CCN1, a Candidate Target for Zoledronic Acid Treatment in Breast Cancer

Ingrid Espinoza1, Hong Liu2, Robert Busby1, and Ruth Lupu1

Abstract

CCN1, also known as CYR61, is a survival and proangiogenic factor overexpressed in about 30% of invasive breast carcinomas, and particularly in triple-negative breast carcinomas (TNBC). CCN1 expression in breast cancer promotes tumorigenicity, metastasis, antihormone, and chemoresistance. TNBCs often develop bone metastasis, thus the vast majority of patients receive bisphosphonate treatment as a companion to chemotherapy. Zoledronic acid (ZOL), a bisphosphonate currently in use, inhibits bone resorption, prevents development of new osteolytic lesions induced by tumor metastasis, and has a direct antitumor activity in breast cancer cells and tumors. We have shown that ZOL inhibits anchorage independent growth as well as branching and morphogenesis in CCN1 overexpressing cells. However, the mechanism is not yet well understood. In this study, we investigate the effect of ZOL in breast cancer cells with high and undetectable CCN1 expression levels. We show that CCN1-expressing cells are more sensitive to ZOL, that ZOL induces downregulation of the CCN1 promoter activity and CCN1 protein expression in a dose-dependent manner, and that ZOL is associated with a decrease in phosphorylated Akt and translocation of FOXO3a, a negative regulator of CCN1 expression, to the nucleus. Deletion of the FOXO3a binding site in the CCN1 promoter prevents ZOL inhibition of the CCN1 promoter activity showing that FOXO3a transcriptional activation is necessary for ZOL to induce CCN1 inhibition. This study provides evidence that ZOL targets the proangiogenic factor (CCN1) through FOXO3a and reveals a new mechanism of ZOL action in breast cancer cells. Mol Cancer Ther; 10(5); 732–41. ©2011 AACR.
breast cancer often develop bone metastases that can cause pathologic fractures. Most patients receive bisphosphonate treatment as a complementary treatment to the chemotherapy. Zoledronic acid (ZOL), a third generation bisphosphonate, is a bisphosphonic acid, a heterocyclic nitrogen-containing bisphosphonate that has an imidazole-ring side chain. The imidazole ring contains 2 critically positioned nitrogen atoms (Fig. 1). ZOL inhibits osteoclast activity and interrupts the cycle of osteoclast-tumor cell interactions (12). ZOL also appears to directly and indirectly inhibit tumor growth (13–15) alone or in combination with chemotherapeutic drugs, molecular targeted agents, and other biological agents (16–18).

In vitro ZOL inhibits the growth of breast cancer cells via apoptosis and cytostasis, exhibits synergistic cytostatic effects with other anticancer drugs, displays antiangiogenesis effects, stimulates T-lymphocyte activity against tumor cells, and modulates tumor cell adhesion and invasion (17, 19–24).

We recently showed that ZOL decreases the transcriptional activity of the CCN1 promoter in androgen-independent prostate cancer cells (25). As a result, we anticipate that CCN1 could be a suitable target to enhance the antitumor effect of ZOL in a subpopulation of breast cancer tumors. CCN1 is overexpressed in aggressive and metastatic breast cancer cells, including MDA-MB-231, H57587T, and BT549 cells, all of which are derived from TNBC (26). Coincidentally, ZOL treatment of MDA-MB-231 cells results in antiproliferative effects in vitro and antiangiogenic effects in vivo (27).

In this study we used cells that express high levels of CCN1 to analyze the inhibitory effect that ZOL had on tumor growth inhibition. Our data suggest a relationship between the antitumor activity of ZOL and CCN1 expression. This association can be explored as a therapeutic initiative for treating the subpopulation of breast cancer patients with high levels of CCN1 expressing tumors.

Material and Methods

Cell culture

Human derived breast cancer cell lines, MDA-MB-231 and MCF-7, were obtained from American Type Culture Collection on 1987 and maintained in monolayer in IMEM medium supplemented with 5% FBS (Fetal Bovine Serum) at 37°C in a humidified 5% CO2 atmosphere. Cells were last time genotyped on August 13, 2010, to ensure their identity using the short tandem repeat profiling method provided by the Genotyping Shared Resource, Mayo Clinic Rochester, MN.

Generation of MCF-7 cells expressing CCN1 full-length cDNA

MCF-7/CCN1 breast cancer cell line was developed by transducing MCF-7 cells with retroviruses containing CCN1 full-length cDNA. A cell line containing the retroviral vector alone was generated as control (MCF-7/pBabe). Both cell lines were established by their resistance to puromycin and by having high level of CCN1 expression (MCF-7/CCN1) or low or undetectable expression levels of CCN1 (MCF-7/pBabe).

Zoledronic acid

Pure crystalline ZOL, in the form of Zometa, was obtained from the Rochester Mayo Clinic Pharmacy. Zometa is produced by Novartis Pharma AG.

Cell viability

Drug sensitivity of breast cancer cells growing in monolayer was determined using a standard colorimetric MTT reduction assay (Promega). Cells were plated at a density of 3,000 cells/100μL/well in 96-well microtiter plates and allowed 24 hours to attach. The medium was then removed and fresh medium containing increasing concentrations of ZOL was added. Control cells were cultured using the same conditions but in the absence of ZOL. When the untreated controls reached confluence the medium was carefully aspirated, MTT dye solution was added and incubated for 4 hours at 37°C. MTT-formazan crystals were dissolved in dimethyl sulphoxide (100 μL/well) and the absorbance was measured at 570 nm in a multi-well plate reader Wallac Victor III (PerkinElmer). Cell viability effects from exposure to ZOL were analyzed plotting concentration-effect curves of the fraction of unaffected (surviving) cells versus drug concentration. For each treatment, cell viability was calculated as a percentage using the following equation: A570 of treated sample/A570 of untreated sample × 100 (A570 Absorbance at 570 nm). Drug sensitivity was...
expressed in terms of the concentration of drug required for 50% (IC50) decrease in cell viability. Because the percentage of control absorbance was considered to be the surviving fraction of cells, the IC50 values were defined as the concentration of drug that produced 50% reduction in control absorbance (by interpolation).

Soft-agar colony formation assays
The efficiency of colony formation in liquid culture was determined by monitoring anchorage-independent cell growth in soft-agar in the presence of increasing concentrations of ZOL. A bottom layer of 1.5 mL (2×) IMEM containing 1.2% agar and 10% FBS was prepared in 6 well plates. After the bottom layer solidified, cells (10,000/well) were added in a 1 mL top layer of 0.7% agar containing increasing concentrations of ZOL (10, 15, and 25 μM/L). All samples were prepared in triplicate. Plates were incubated in a humidified 5% CO2 incubator at 37°C. At day 8 colonies measuring 50 or more μm were counted using a cell colony counter (Optronix GelCount; Oxford Optronic). With this assay we determined that ZOL inhibits the anchorage-independent growth typical for the metastatic MDA-MB-231 cells.

Annexin V–FITC/PI assay of apoptotic cells
The Annexin V–FITC Kit (Promega) was used to assess apoptotic cell death. The assay was carried out as directed by the manufacturer. Briefly, cells were harvested and resuspended in Annexin V binding buffer. Then 10μL of propidium iodine (PI; 50 μg/mL) and 5μL of Annexin V–FITC were added per reaction. Samples were incubated 15 min in the dark and then analyzed by flow cytometry. The samples were analyzed in a FACScalibur flow cytometer (Becton Dickinson). Cell Quest software (Becton Dickinson) was used for data acquisition and analysis.

Three-dimensional culture on Matrigel
The 3-dimensional cell culture assays were carried out as previously described (28). Briefly, single-cell suspensions of cells were prepared using trypsin. In an 8-well chamber slide, on top of a polymerized layer of 100% Matrigel, 2 × 10⁵ cells/well were plated in 0.4 mL of 2% Matrigel in IMEM medium containing increasing concentrations of ZOL (5, 10, and 25 μM/L). Cultures were kept for 5 days. Phase-contrast images were obtained under ×100 magnification.

CCN1-transcription assay
Cells were seeded (2 × 10⁴) in 24-well plates in IMEM medium containing 10% FBS. After 24 hours, cells were washed and then transiently transfected with luciferase reporter constructs using FuGene6 reagent (Roche Biochemicals) according to the manufacturer’s instructions. Briefly, cells were transiently transfected with: (i) an internal control plasmid pRL-CMV (50 ng/well); (ii) empty vector (pGL3; 500 ng/well); CCN1-promoter (pGL3-CCN1-Luc; 500 ng/well); (iii) CCN1 promoter containing a FOXO3a deletion (pGL3-ΔFOXO3a-Luc; 500 ng/well); (iv) CCN1 promoter containing a deletion in the –176 region (pGL3-Δ176-Luc; 500 ng/well), and (v) CCN1 promoter containing a AP-1 deletion (pGL3-AAP-1-Luc; 500 ng/well). The internal control plasmid was used to correct for transfection efficiency. After 24 hours of the transfection cells were washed with fresh media, treated and incubated in fresh medium containing 10% FBS supplemented with increasing concentrations of ZOL 10, 15, and 25 μM/L in IMEM containing 10% FBS. Twenty four hours after ZOL treatments the cell extracts were prepared and luciferase activity was measured using a Dual Luciferase Assay Kit (Promega) according to the manufacturer protocol using a luciferase multi-well plate reader Wallac Victor III (PerkinElmer). Quadruplicate luciferase activities were normalized to Renilla luciferase (pRL-CMV) and the ratios between luciferase/Renilla activities were determined.

Immunoblotting analysis
Cells were seeded in 6 well plates and allowed an overnight period for attachment. The medium was then removed and fresh medium, along with various concentrations of ZOL, was added. Control cells without the agent were cultured using the same conditions with comparable medium changes. Cells were treated for 24 hours. The next day, cells were harvested, washed twice with PBS and then lysed with 1 × cell lysis buffer (Cell Signaling) for 30 minutes on ice with vortexing every 5 minutes. The lysates were then cleared by centrifugation (10 minutes at 14,000 rpm – 4°C). Protein concentration was determined using the Pierce BCA Protein Assay Kit (Pierce). Equal amounts of protein (30 μg) were resuspended in 5 × 10⁵ marker Reducing Sample Buffer (Thermo Scientific) and denatured for 5 minutes at 99°C. Then the proteins were resolved by electrophoresis on 10% polyacrylamide gel (Criterion XT Bis-Tris precast gel; Bio-Rad), and transferred onto PVDF membrane (Amershand Biosciences). The membranes were blocked with TBS-T (TBS and 0.5% Tween 20) containing 5% (w/v) nonfat dry milk for 1 hour and incubated with a rabbit anti-CCN1 (H78) polyclonal antibody (1:2,000; Santa Cruz Biotechnology) for 1 hour at room temperature. Different membranes were blocked with 5% BSA for 1 hour and incubated with the polyclonal anti-MAPK, anti-phospho-MAPK, anti-Akt and anti-phospho-Akt antibodies (1:2,000; Cell signaling) overnight at 4°C. The membrane to detect FOXO3a was blocked with 5% milk and incubated overnight with a polyclonal anti-FOXO3a antibody (1:1,000; Upstate). After 3 washings with TBS-T, blots were incubated with 1:2,000 dilution of horseradish peroxidase-linked donkey anti-rabbit IgG secondary antibody. Proteins were detected by the enhanced chemoluminescence reaction using Hyperfilm (Amershams-Pharmacia).

Statistical analysis
Data are expressed as mean ± SEM. ANOVA and Tukey–Kramer Multiple Comparisons were used to determine statistical significance using GraphPad Prism.
Zoledronic Acid Inhibits CCN1 in MDA-MB-231 Cells

Version 4.0 statistical package). A P-value of less than 0.05 was considered significant.

Results

ZOL inhibits growth and induces apoptosis of CCN1-overexpressing breast cancer cells

The viability of MDA-MB-231 cells, which express high levels of endogenous CCN1 (7), was considerably reduced after the treatment of ZOL in a dose-dependent manner (Fig. 2A). Additionally, we tested the effect of ZOL on a cell line engineered to overexpress CCN1 (MCF-7/CCN1) and their vector control cell line (MCF-7/pBabe). Strikingly, we observed that MCF-7/CCN1 cells were as sensitive as the MDA-MB-231 cells to ZOL. (Fig. 2A; the IC50 for MDA-MB-231 was 6.3 μmol/L and the IC50 for the MCF-7/CCN1 was 5.6 μmol/L). Remarkably, ZOL inhibited anchorage-dependent and anchorage-independent growth of MDA-MB-231 cells by about 90% (P < 0.05; Fig. 2B for anchorage-independent growth). ZOL had no effect on the growth of MCF-7/pBabe cells (data not shown). Cell culture in 2D suggests that ZOL treatment affected the cell growth of MDA-MB-231 and MCF-7/CCN1 cells in a dose-dependent manner (Fig. 2C). To assure that the effect of ZOL was not due to toxicity, we determined whether ZOL induced apoptotic cell death in MDA-MB-231 cells. Apoptosis was determined by Annexin V–FITC staining and PI labeling. Early apoptotic cells were positive for Annexin V and negative for PI and then analyzed by flow cytometry. ZOL treatment of MDA-MB-231 cells resulted in increased staining for Annexin V in a dose-dependent manner (Fig. 2D). The number of apoptotic cells (7%–35%) augmented with increased doses of ZOL (0–100 μmol/L; P < 0.05). Necrosis induced by ZOL was observed only at 50 and 100 μmol/L of ZOL (Fig. 2D). Overall, our results suggest that breast cancer cells expressing CCN1 are sensitive to ZOL treatment inducing cell death by apoptosis.

ZOL inhibits branching and morphogenesis of CCN1 expressing cells

To explore whether ZOL affects the growth of MDA-MB-231 cells in 3D cell culture, we cultivated these cells on Matrigel in the presence of increasing concentrations of ZOL (5, 10, and 25 μmol/L) for 5 days. We found that ZOL inhibited branching and morphogenesis of MDA-MB-231 cells in a dose-dependent manner reaching maximum effect at 10 μmol/L (Fig. 3). Our results show that ZOL perturbs morphogenesis and further suggest the likelihood that ZOL could also inhibit tumor invasion and metastasis. Similar results were obtained with other CCN1 expressing cells including HS578T and BT549 (data not shown).

ZOL inhibits CCN1-promoter activity and CCN1-protein expression

To determine whether ZOL regulates CCN1-promoter activity MDA-MB-231 cells were transfected with a Luciferase-CCN1 reporter containing 884bp (from –1093 to –209 upstream of translation start site) and assessed the CCN1 transcriptional activity in response to increasing concentrations of ZOL for 24 hours (Fig. 4A). Parallel studies were conducted to assess the regulation of CCN1 at the protein level. Cells plated in a 6 well/plate were treated with increasing concentrations of ZOL. Cells lysates were prepared and blotted using an anti-CCN1 antibody (Fig. 4B). Results show that ZOL inhibits CCN1 promoter activity in a dose-dependent manner and that it inhibits CCN1 expression at the protein level.

Exogenous CCN1 impairs the ZOL effect on CCN1-promoter activity

In additional experiments, we determined whether exogenous CCN1 can modulate the ZOL effect on CCN1-promoter. MDA-MB-231 cells were transfected with pGL3-CCN1-Luc promoter and the activity was measured in the presence or absence of increasing concentrations of CCN1 recombinant protein and the optimal dose of ZOL (15 μmol/L). Our results show that exogenous CCN1 protein reverts ZOL inhibition of CCN1 transcription (Fig. 5), therefore suggesting that ZOL has a specific effect on CCN1 promoter.

Transcriptional regulation of CCN1 gene by ZOL is dependent on FOXO3a

CCN1 contains different binding sites for transcription factors that regulate its expression (29). Transcriptional regulation of CCN1 promoter wild type and CCN1-promoter containing different deletions was assessed using Luciferase-reporter assay. The constructs used were: (i) pGL3-ΔFOXO3a-Luc, (ii) pGL3-ΔAP1-Luc, and (ii) deletions to positions –936 (pGL3-ΔAP1-Luc). Results showed that deletions at the positions –176 (pGL3-ΔAP1-Luc) and –936 (pGL3-ΔAP1-Luc) resulted in a strong inhibitory effect in the CCN1 promoter activity even in the absence of ZOL treatment (Fig. 6A). Previous studies showed that the promoter of the human CCN1 gene contains a forkhead 3a binding motif (FOXO3a; ref. 30). To study the role of FOXO3a in the transcriptional regulation of CCN1, a deletion mutant of the CCN1 promoter was generated (from –565 to –209 upstream of ATG; pGL3-ΔFOXO3a-Luc; Fig. 6B). Then the transcriptional activity of CCN1-promoter-Luc reporter constructs pGL3, pGL3-CCN1-Luc, and pGL3-ΔFOXO3a-Luc was analyzed after treatment with increasing concentrations of ZOL (Fig. 6C). As we expected increasing concentrations of ZOL reduced the transcriptional activity of the wild type CCN1-promoter.

ZOL inhibition of CCN1 results in a significant decrease in Akt signaling

MDA-MB-231 cells were treated with increasing concentrations of ZOL for 24 hours. The cells were then lysed and the proteins were resolved using a 10% acrylamide gel and visualized by Western blotting analysis using specific antibodies against Akt, pAkt, MAPK, pMAPK,
Figure 2. ZOL inhibits the growth and induces apoptosis in cells overexpressing CCN1. A, to evaluate how ZOL affects metastatic breast cancer cell viability MTT-based metabolic assays (as described in Materials and Methods) in cells overexpressing endogenous CCN1 (MDA-MB-231) and CCN1 overexpressing cells (MCF-7/CCN1) were cultured in the absence or presence of equimolar concentrations of ZOL for 3 days. B, ZOL inhibits the anchorage-independent growth of MDA-MB-231 cells. The ability of MDA-MB-231 cells to grow in soft agar in the presence/absence of ZOL was assessed using anchorage-independent colony-formation assay. Subconfluent breast cancer cells were plated (10,000 cells/well) in triplicate in 6 well plates for anchorage-independent soft agar assay as previously described (49). Cells were cultured in the absence or in the presence of different concentrations of ZOL (5, 10, 15, and 25 μmol/L) for around 8 days at 37°C and 5%CO2. Colonies were counted using the colony counter machine. Data are representative of 3 independent experiments. C, ZOL induces cell death in cells overexpressing CCN1. The effect of different concentrations of ZOL on MDA-MB-231 and MCF-7/CCN1 compared with MCF-7/pBabe (empty vector) cells were observed in 2D culture and photographed in an inverted microscope. D, ZOL induces apoptosis in MDA-MB-231 cells in a dose-dependent manner. The cell death induced by ZOL in MDA-MB-231 cells was assessed by Annexin V. Briefly, MDA-MB-231 cells were treated with different concentrations of ZOL (10, 15, 25, 50, and 100 μmol/L) for 48 hours. Then cells were harvested and stained for Annexin V following the instructions of the kit. After staining, cells were analyzed by FACScalibur flow cytometry. Cell Quest software was run for data acquisition and Modfit software for analysis. Data are shown as mean ± SEM of 3 independent experiments. *, P < 0.05 from control cells. **, P < 0.01 from control cells.
and FOXO3a. Our results show that ZOL treatment blocks activation of Akt (Fig. 7A) and induces FOXO3a expression in the nuclear fraction (Fig. 7B), thus suggesting a molecular mechanism for the cellular and molecular effects mediated by ZOL on CCN1-overexpressing breast cancer cells.

Discussion

Our early studies using MDA-MB-231, HS578T, and BT549 breast cancer cells showed that CCN1, an angiogenic factor overexpressed in these cells, is actively involved in the acquisition of an estrogen-independent breast cancer phenotype (8, 31). CCN1 was found to be overexpressed in a subgroup of breast cancer cell lines derived from TNBC, which have a unique molecular profile, aggressive behavior, distinct patterns of metastasis, and lack of targeted therapies (8, 32). Moreover, forced expression of CCN1 in MCF-7 cells induced their progression to become hormone independent, similar to triple negative breast cancer cells (7).

Metastatic bone disease is the main cause of morbidity in breast cancer patients (33). Bisphosphonates are potent antiresorptive drugs that inhibit the action of osteoclasts. Interestingly, bisphosphonates seem to have a direct antitumor effect in addition to their indirect effect through the inhibition of osteoclasts decreasing the concentration of tumor growth promoting molecules. Emerging results indicate significant clinical benefit especially when combined with other drugs, e.g., chemotherapeutic agents (34). ZOL belongs to the latest generation of bisphosphonates and is considered to be the most potent one clinically available. Therefore, it is suitable to use ZOL as a reference substance when evaluating new bisphosphonates derivatives to estimate their relative efficacy. The recognized mechanism of action for ZOL is known to be mediated through the inhibition of farnesyl pyrophosphate synthase (35) and protein geranylgeranylation (36). We recently showed that CCN1 enhances the antitumor effects of ZOL in prostate carcinomas (25). These findings motivated us to investigate whether the effect of ZOL observed in other carcinomas is also found in breast cancer cells overexpressing CCN1.

In this study we showed that treatment with ZOL specifically decreased viability of cells overexpressing CCN1, including MDA-MB-231 and MCF-7/CCN1 cells, as compared to the control MCF-7 cells which do not express CCN1 (Fig. 2A). We also showed that ZOL inhibits anchorage-independent growth in a dose-dependent manner (Fig. 2B) exclusively on CCN1 overexpressing...
breast cancer cells. Our results are consistent with other studies showing that ZOL inhibits MDA-MB-231 cell viability by affecting changes in cell growth and apoptosis (37). More importantly, studies in human myeloma cells show that nitrogen-containing bisphosphonates, including ZOL, inhibit cell proliferation (38). The apoptotic effect of bisphosphonates such as pamidronate, incadronate, and ZOL on cancer cells has been reported in several systems including macrophages, osteoclasts and myeloma cells (38–40). In addition, we showed that ZOL inhibits branching and morphogenesis of triple negative breast cancer cells in a 3D Matrigel cell culture assay (Fig. 3) and that ZOL induces apoptotic cell death at higher concentrations (50–100 μmol/L; Fig. 2D). Our results are analogous to previous reports showing that higher doses of ZOL are required to induce apoptosis of endothelial progenitor cells (>25 μmol/L in the present study, 100 μmol/L in the study using mature endothelial cells (41) and in breast cancer cells (37)], which implies that perhaps ZOL affects both angiogenesis and vasculogenesis.

Previously, we showed that CCN1 induces metastasis and drug resistance in breast cancer cells (31). Following our reported findings we then studied the mechanism by which ZOL induces growth inhibition and apoptosis of CCN1 overexpressing cells. Initially we showed that ZOL regulated the expression of CCN1 at the protein level (Fig. 4B). These data are consistent with our previous reported results which show that ZOL downregulates CCN1 in prostate cancer (25). We then showed that increasing concentrations of ZOL

Figure 5. Exogenous CCN1 impair the ZOL effect on CCN1-promoter activity in MDA-MB-231 cells. MDA-MB-231 cells were transfected with the wild type CCN1-promoter (pGL3-CCN1-Luc) and after 24 hours cells were treated with 15 μmol/L ZOL or in the presence or absence of increasing concentrations of CCN1 recombinant protein (CCN1-GST). *, P < 0.05 versus control cells (untreated); **, P < 0.01 versus control cells; #, P < 0.05 versus cells treated with 15 μmol/L ZOL.

Figure 6. Inhibition of CCN1-promoter activity by ZOL is dependent on FOXO3a binding site. A, transcriptional regulation of CCN1 promoter wild type and CCN1-promoter containing different deletions was assessed using luciferase-reporter assay. The constructs used were: (i) -565 (pGL3-ΔFOXO3a-Luc), (ii) -176 (pGL3-Δp-176-Luc), and (iii) -936 (pGL3-ΔAP1-Luc). *, P < 0.05 versus control cells (transfected with CCN1 full length) and ***, P < 0.001 versus control cells. B, diagrammatic representation of the promoter of CCN1 with various selected transcription-binding sites. The FOXO3a binding motif (AAAGCAAAACA) is shown in the schema. The plasmid vector containing luciferase reporter gene was used in all the reporter assays. pGL3-CCN1-Luc is the plasmid with full sequence of CCN1 promoter. C, the inhibitory effect of ZOL on CCN1-promoter is mediated by FOXO3a binding site. MDA-MB-231 cells were transfected with pGL3-CCN1-Luc promoter or pGL3-ΔFOXO3a-Luc containing the FOXO3a deletion and then treated with increased concentrations of ZOL for 24 hours. *, P < 0.05 versus control cells (untreated) transfected with pGL3-CCN1-Luc promoter; #, P < 0.05 in cells transfected with pGL3-CCN1-Luc and treated with different concentrations of ZOL relative to control cells (untreated) transfected with the pGL3-CCN1-Luc.
inhibited the transcriptional activation of CCN1 in triple negative-derived breast cancer cells. To ascertain that the inhibitory effect of ZOL was directed against the CCN1-promoter activity and the translation of CCN1, we carried out a competitive experiment between ZOL and CCN1. MDA-MB-231 cells were incubated with 15 μmol/L ZOL and with increased concentrations of CCN1-GST protein for 24 hours. Results showed that CCN1 reverts the inhibitory effect of ZOL (Fig. 5). Our findings reveal that ZOL specifically inhibits CCN1 expression which results in inhibition of cell proliferation and induction of apoptotic cell death in cells over-expressing CCN1.

With this study we show that cell proliferation of CCN1-overexpressing breast cancer cells that spread and create osteolytic metastasis are inhibited by ZOL. A concentration of 10 μmol/L is required to induce significant inhibition of anchorage independent growth concomitantly with downregulation of CCN1. Concentration greater than 50 μmol/L of ZOL were necessary to induce apoptosis which is consistent with another in vitro study (37) showing that in the local bone microenvironment higher doses than in the serum may be needed. Previous studies show that ZOL alone does not inhibit tumor growth of MDA-MB-231 xenografts. Combination treatment of ZOL and doxorubicin (42) or doxycycline (43) or specific antibodies (27) inhibits the growth of breast tumors.

CCN1 contains the forkhead factor binding motif AAAGCAAAACA in its promoter region. It has been shown that FOXO3a is a negative regulator of CCN1 in the muscle (30). Because ZOL inhibited CCN1 expression at transcriptional level affecting the CCN1-promoter activity, we speculated that a specific binding site at the CCN1 promoter is the molecular mechanisms by which ZOL induces inhibition of breast cancer growth and induces apoptosis. Our studies revealed that all the transcription-binding sites mutated at the CCN1 promoter (Fig. 6A) were critical for the CCN1 promoter activity. Nevertheless, the deletion of the FOXO3a binding site was the only deleted site on CCN1 promoter that showed a partial activity and that completely abolished ZOL inhibition of CCN1 transcriptional activity (Fig. 6B and C). This was remarkable, because forkhead transcription factors are key players, under regulation of Akt, including a series of biological properties such as cellular proliferation, morphogenesis, and apoptosis (44). In view of the previous results we next determined that ZOL induced a significant decrease in Akt activation and concomitantly induced the accumulation of FOXO3a in the nucleus (Fig. 7A and B, respectively). No changes in MAPK activation were observed (Fig. 7A), thus showing that blockage of CCN1 by ZOL is specifically driven through the FOXO3a/Akt survival pathway.

Although ZOL has clear antiproliferative and apoptotic effects in vitro and in vivo, a critical issue to its potential clinical use is the transient maximum concentration in circulation. ZOL reaches 2 μmol/L in the blood in a very short time (45). We showed that ZOL at 10 μmol/L induces growth inhibition. We anticipate that 95 μg/kg ZOL will be the appropriate dose for in vivo (athymic nude mice) treatments which closely corresponds to 3.8 mg/m² ZOL, the dose currently used for patient’s treatment. In humans, following intravenous infusion, ZOL concentrations decline in a triphasic fashion: the early distribution half-life is 0.23 hours; the elimination half-life is 1.75 hours and the terminal elimination half-life is 167 hours. Here we show that ZOL targets CCN1, CCN1 is expressed in the tumor site, thus, it is a strong probability that 2 μmol/L ZOL would fully reach the tumor site.

When ZOL is used as a single agent for cancer treatment its high bone mineral affinity decreases significantly its bioavailability weakening its in vivo antitumor potential. Several preclinical studies showing that ZOL alone does not inhibit the growth of MDA-MB-231 xenografts have been published (27, 42, 43). One can envision treatment strategies where ZOL is combined with synergistic chemotherapies or with agents able to decrease the bone mineral affinity of bisphosphonates. The rapid postinfusion decline of ZOL...
Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors thank Drs. Hyo-Soo Kim and Brahim Chouqar for kindly providing the constructs for the CCN1 promoter. In addition, they also thank Dr. Michele Caraglia and Julian Molina for scientific discussion, Dr. Christian R. Gomez for critical review of the manuscript, and Dr. Cheol H. Park and Mr. Alejandro Lupu for editing the manuscript.

Grant Support

This work was supported by the award NIH R01 CA118975 grant (R. Lupu). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 3, 2010; revised January 17, 2011; accepted February 3, 2011; published OnlineFirst March 10, 2011.

References


Molecular Cancer Therapeutics

740 Mol Cancer Ther; 10(5) May 2011

Published OnlineFirst March 10, 2011; DOI: 10.1158/1535-7163.MCT-10-0836

Espinoza et al.
Molecular Cancer Therapeutics

CCN1, a Candidate Target for Zoledronic Acid Treatment in Breast Cancer

Ingrid Espinoza, Hong Liu, Robert Busby, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-10-0836

Cited articles
This article cites 49 articles, 14 of which you can access for free at:
http://mct.aacrjournals.org/content/10/5/732.full#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
http://mct.aacrjournals.org/content/10/5/732.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.